Funding for this research was provided by:
Text and Data Mining valid from 2020-01-07
Received: 6 August 2019
Accepted: 29 November 2019
First Online: 7 January 2020
Ethics approval and consent to participate
: Participants provided written consent to participate in the ArthritisPower registry and were asked to opt-in if they wished to participate in the Barriers to RA Treatment sub-study. The study was reviewed and deemed exempt by the Schulman Institutional Review Board (SAIRB; now Advarra).
: All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.
: MSS, JLS, and MY are employees and stockholders of the UCB Pharma. JRC received grant/research and consultancy fees from the AbbVie, Amgen-Roche, Bristol-Myers Squibb, Corrona, Crescendo, Genentech, Janssen, Pfizer, and UCB Pharma. All other authors declare that they have no competing interests.